CardioKinetix Obtains $44,000,000 Series E Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d8ea8f74-ed68-497d-9ea2-13b57b2499a4&Preview=1 -
Date
9/21/2011 -
Company Name
CardioKinetix -
Mailing Address
925 Hamilton Avenue Menlo Park, CA 94025 -
Company Description
CardioKinetix, Inc. is developing new technology for treating Congestive Heart Failure (CHF). This is a catheter-based intervention implanted into the heart. CHF results from damage to the heart from several causes, which affects nearly five million people in the U.S. -
Website
http://www.cardiokinetix.com -
Transaction Type
Venture Equity -
Transaction Amount
$44,000,000 -
Transaction Round
Series E -
Proceeds Purposes
This financing provides CardioKinetix the capital necessary to substantially progress the development of our PARACHUTE™ device, including conducting clinical studies to further support the initial commercialization of Parachute in Europe and a PMA submission to FDA. -
M&A Terms
-
Venture Investor
SV Life Sciences -
Venture Investor
New Leaf Venture Partners -
Venture Investor
U.S. Venture Partners -
Venture Investor
JPMorgan Partners -
Venture Investor
Undisclosed
